Efficacy and safety of transcatheter arterial chemoembolization combined with targeted therapy and immunotherapy in treatment of patients with stage Ⅱb/Ⅲa hepatocellular carcinoma based on China Liver Cancer Staging
Objective To evaluate the efficacy and safety of first-line transcatheter arterial chemoembolization(TACE)combined with targeted therapy and immunotherapy in the treatment of patients with stage Ⅱb/Ⅲa hepatocellular carcinoma(HCC)based on China Liver Cancer Staging(CNLC).Methods A total of 198 patients who received first-line TACE combined with targeted therapy and immunotherapy or received TACE alone from January 2015 to December 2022 in the First Affiliated Hospital of Soochow University were enrolled in this study,and after propensity score matching,there were 50 patients in combination group and 50 patients in TACE group.The Kaplan-Meier method was used to calculate median overall survival(mOS)and median progression-free survival(mPFS).Modified Response Evaluation Criteria in Solid Tumors was used to evaluate objective response rate(ORR)and disease control rate(DCR),and Common Terminology Criteria for Adverse Events v5.0 was used to evaluate adverse events.The chi-square test was used for comparison of categorical data between two groups;the t-test was used for comparison of normally distributed continuous data between two groups,and the Wilcoxon rank-sum test was used for comparison of non-normally distributed continuous data between two groups.The Kaplan-Meier method was used to estimate survival time and calculate 95%confidence interval(CI),and the Log-rank test was used for comparison of mOS and mPFS between two groups.Results The combination group had an mOS of 30.1 months(95%CI:21.9—38.3),and the TACE group had an mOS of 14.5 months(95%CI:11.0—18.0),with a significant difference between the two groups(χ2=17.8,P<0.001);the combination group had an mPFS of 10.3 months(95%CI:8.8—11.8),and the TACE group had an mPFS of 7.1 months(95%CI:5.8—8.4),with a significant difference between the two groups(χ2=10.4,P<0.001).There were significant differences between the combination group and the TACE group in ORR(84%vs 58%,P<0.05)and DCR(94%vs 80%,P<0.05).There was no significant difference between the combination group and the TACE group in the incidence rate of adverse events(24%vs 16%,P=0.317),and no adverse event-related deaths were observed in either group.Conclusion Compared with TACE alone,TACE combined with targeted therapy and immunotherapy has a better efficacy in the treatment of patients with CNLC stage Ⅱb/Ⅲa HCC,without increasing the incidence rate of severe adverse events.
国家科技期刊平台
NSTL
万方数据
